- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01821664
Vascular Graft Infections (VASGRA)
May 5, 2015 updated by: University of Zurich
Vascular Graft Infections - Epidemiology, Best Treatment Options, Imaging Modalities and Impact of Negative Pressure Wound Therapy
Background: Vascular grafts are increasingly implanted due to an increasing prevalence of atherosclerosis and diabetes, and about 1-6% of vascular procedures are complicated by infection.
Mortality attributable to prosthetic vascular graft infections (PVGI) is high.
However, there are almost no data regarding best treatment options of such complicated infections.
Most recommendations are based on expert opinion and not on clinical trials or cohort observational data analyses.
Evaluating infectious and other complications after vascular surgery procedures are important, and additionally, such studies may offer insights for quality improvement and improved patient outcomes.
With the first aim investigators will establish an infrastructure for studying PVGI in Zurich.
Investigators will take advantage of the Swissvasc registry, a central registry which collects preoperative, operative and discharge data regarding the index vascular surgical interventions.
They will create a prospective observational cohort database of all patients who receive a vascular graft (peripheral, aortic, vein) at the University hospital of Zurich (VASGRA Cohort A).
Patients with a PVGI will be included in VASGRA Cohort B and followed up using a flow chart with a focus on the course of this infectious complication.
Additionally, investigators will establish a biobank with the collection of tissue- and blood samples of patients with PVGI.
With the second aim researchers will investigate different diagnostic, clinical and therapeutic research questions nested in the VASGRA Cohort.
Firstly, they will address epidemiological questions, such as: determine the incidence and outcome of complications after vascular graft placement; determine risk factors, best treatment strategies and outcome of PVGI, and determine the influence of different antibiotic regimens on the outcome of PVGI due to different bacterial pathogens.
Secondly, investigators will determine the accuracy of different imaging techniques (PET/CT and MRI) for the diagnosis of PVGI, and their individual role for the assessment of treatment response.
Thirdly, investigators will evaluate the bacterial diversity of vascular wound infections using 16s r-Ribonucleic acid (RNA)amplification, and investigators will explore whether this bacterial diversity does predict disease progression.
Here, investigators will also study the impact of negative pressure wound therapy (NPWT) on bacterial diversity in the treatment course of PVGI.
Fourthly, investigators will look for cut-off levels of relevant blood leucocytes count, C-reactive protein and procalcitonin raising suspicion of a PVGI.
Lastly, investigators will look at histopathological features of excised vascular grafts.
Expected value of the project: Results from the proposed study are an important contribution to the field, based on the large sample size, longitudinal design and by unifying clinical and epidemiological science.
The very well characterized patient groups and the close connection between vascular surgeons, infectious disease specialists, specialists in nuclear medicine and microbiologist will help to investigate PVGI in depths.
Investigators hope to be able to develop guidelines regarding best diagnostic modalities and treatment options in case of vascular graft infections.
In the future we plan to examine bacteria retrieved from the PVGI in the laboratory in detail.
The recovered bacteria will be examined for antimicrobial susceptibility and their capability to form biofilms.
Furthermore investigators will examine how bacterial recovery form explanted grafts could be optimized.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
1800
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Barbara Hasse, MD
- Phone Number: +41 (0)44 255 11 11
- Email: barbara.hasse@usz.ch
Study Locations
-
-
ZH
-
Zurich, ZH, Switzerland, 8091
- Recruiting
- University Hospital Zurich, Div of Infectious Diseases and Hospital Epidemiology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
All patients with a vascular surgery at the University hospital will be included in the study.
Description
Inclusion criteria:
Control patients:
- Vascular graft surgery (peripheral, aortic, vein)
Case patients:
- Patients with previous primary implantation of an aortic or peripheral vascular implant and suspicion of PVGI
- Age >18 years
- Written informed consent
Exclusion criteria:
- Drug or alcohol abuse
- Involvement in a conflicting clinical trial (investigational drug)
- Inability to follow the procedures of the cohort, e.g. due to language problems, psychological disorders or dementia of the subject
- Known or suspected non-compliance
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Prosthetic vascular graft implantation, follow up
|
Implantation of a prosthetic vascular graft
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vascular graft infection
Time Frame: within 10 years
|
Persons are followed up after vascular graft surgery.
|
within 10 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Bleeding
Time Frame: 10 years
|
10 years
|
Foreign body reaction
Time Frame: 10 years
|
10 years
|
All cause- mortality
Time Frame: 10 years
|
10 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Barbara Hasse, MD, University Hospital Zurich, Div of Infectious Diseases and Hospital Epidemiology
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Husmann L, Huellner MW, Ledergerber B, Anagnostopoulos A, Stolzmann P, Sah BR, Burger IA, Rancic Z, Hasse B; and the Vasgra Cohort. Comparing diagnostic accuracy of 18F-FDG-PET/CT, contrast enhanced CT and combined imaging in patients with suspected vascular graft infections. Eur J Nucl Med Mol Imaging. 2019 Jun;46(6):1359-1368. doi: 10.1007/s00259-018-4205-y. Epub 2018 Nov 13.
- Anagnostopoulos A, Ledergerber B, Kuster SP, Scherrer AU, Naf B, Greiner MA, Rancic Z, Kobe A, Bettex D, Hasse B; VASGRA Cohort Study. Inadequate Perioperative Prophylaxis and Postsurgical Complications After Graft Implantation Are Important Risk Factors for Subsequent Vascular Graft Infections: Prospective Results From the Vascular Graft Infection Cohort Study. Clin Infect Dis. 2019 Aug 1;69(4):621-630. doi: 10.1093/cid/ciy956.
- Husmann L, Ledergerber B, Anagnostopoulos A, Stolzmann P, Sah BR, Burger IA, Pop R, Weber A, Mayer D, Rancic Z, Hasse B; VASGRA Cohort Study. The role of FDG PET/CT in therapy control of aortic graft infection. Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):1987-1997. doi: 10.1007/s00259-018-4069-1. Epub 2018 Jun 11.
- Ajdler-Schaeffler E, Scherrer AU, Keller PM, Anagnostopoulos A, Hofmann M, Rancic Z, Zinkernagel AS, Bloemberg GV, Hasse BK; and the VASGRA Cohort. Increased Pathogen Identification in Vascular Graft Infections by the Combined Use of Tissue Cultures and 16S rRNA Gene Polymerase Chain Reaction. Front Med (Lausanne). 2018 Jun 4;5:169. doi: 10.3389/fmed.2018.00169. eCollection 2018.
- Husmann L, Sah BR, Scherrer A, Burger IA, Stolzmann P, Weber R, Rancic Z, Mayer D, Hasse B; VASGRA Cohort. (1)(8)F-FDG PET/CT for Therapy Control in Vascular Graft Infections: A First Feasibility Study. J Nucl Med. 2015 Jul;56(7):1024-9. doi: 10.2967/jnumed.115.156265. Epub 2015 May 14.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2013
Primary Completion (Anticipated)
March 1, 2023
Study Completion (Anticipated)
March 1, 2023
Study Registration Dates
First Submitted
March 7, 2013
First Submitted That Met QC Criteria
March 26, 2013
First Posted (Estimate)
April 1, 2013
Study Record Updates
Last Update Posted (Estimate)
May 6, 2015
Last Update Submitted That Met QC Criteria
May 5, 2015
Last Verified
May 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KEK-ZH-Nr. 2012-0583
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prosthetic Vascular Graft Infection
-
Osteal Therapeutics, Inc.Active, not recruitingProsthetic-joint InfectionUnited States
-
Vivantes Netzwerk für Gesundheit GmbHUnknownProsthetic Joint Infection | Infections Joint Prosthetic | Wear of Articular Bearing Surface of Internal Prosthetic Joint | Infection Prosthetic | Prosthetic PainGermany
-
Charite University, Berlin, GermanyUnknownHip Prosthetic Joint Infection | Knee Prosthetic Joint Infection | Shoulder Prosthetic Joint Infection
-
University Hospital, Basel, SwitzerlandActive, not recruitingProsthetic-joint InfectionSwitzerland
-
fang guofangUnknownDefect; Internal Prosthetic Device, Implants and Grafts, Orthopedic, Bone GraftChina
-
University Hospital, MontpellierNot yet recruitingProsthetic-joint Infection
-
Osteal Therapeutics, Inc.AvailableProsthetic-joint Infection
-
University Hospital, ToursPfizer; International Clinical Trials AssociationUnknownEfficacy and Safety Study of Antibiotic Treatment to Treat Hip Prosthetic Joint Infection (LIZ-BONE)Hip Prosthetic Joint InfectionFrance, Spain, Italy
-
Center for Innovation and Research OrganizationEnrolling by invitation
-
Istituto Ortopedico GaleazziUnknown
Clinical Trials on Prosthetic vascular graft
-
Harvard Medical School (HMS and HSDM)RecruitingImplant ComplicationUnited States
-
NonWoTecc Medical GmbHMDT Medical Device Testing GmbHTerminatedPeripheral Arterial Disease | Peripheral Vascular DiseaseGermany
-
W.L.Gore & AssociatesCompleted
-
Angiotech PharmaceuticalsTerminatedHyperplasia | End Stage Renal Failure on DialysisUnited States
-
Maquet CardiovascularTerminatedPeripheral Arterial Occlusive Disease (PAOD)Germany, Austria
-
Vascutek Ltd.RecruitingAneurysm | Aortic Diseases | Carotid Artery Injuries | Aortic Arch | Dissection | Aortic Root Aneurysm | Aortic Root Dissection | Bypass Extremity Graft | Occlusive Vascular DiseaseUnited States, Belgium, France, Hungary, Germany, Netherlands, Canada
-
Humacyte, Inc.FGK Clinical Research GmbHActive, not recruitingKidney Failure, Chronic | End-stage Renal DiseasePoland
-
Maquet CardiovascularUnknownAortic Aneurysm, Abdominal | Occlusive Disease of Artery of Lower ExtremityAustria, Germany
-
LeMaitre VascularTerminatedEnd Stage Renal DiseaseUnited States
-
Hôpital NOVOCompleted